38 results on '"Chelle, Pierre"'
Search Results
2. A personalized limited sampling approach to better estimate terminal half‐life of FVIII concentrates
3. Infliximab in paediatric inflammatory bowel disease: External evaluation of population pharmacokinetic models.
4. Canadian clinical experience on switching from standard half‐life recombinant factor VIII (rFVIII), octocog alfa, to extended half‐life rFVIII, damoctocog alfa pegol, in persons with haemophilia A ≥ 12 years followed in a Comprehensive Hemophilia Care Program in Canada
5. External qualification of the Web‐Accessible Population Pharmacokinetic Service–Hemophilia (WAPPS‐Hemo) models for octocog alfa using real patient data
6. Terminal half‐life of FVIII and FIX according to age, blood group and concentrate type: Data from the WAPPS database
7. Use of population PK/PD approach to model the thrombin generation assay: assessment in haemophilia A plasma samples spiked by a TFPI antibody
8. Development of a Plasminogen Population PK model supporting prophylactic replacement therapy for Plasminogen deficient patients within the WAPPS‐Hemo platform.
9. Development and Validation of a Population-Pharmacokinetic Model for Rurioctacog Alfa Pegol (Adynovate®): A Report on Behalf of the WAPPS-Hemo Investigators Ad Hoc Subgroup
10. Comparative pharmacokinetics of two extended half‐life FVIII concentrates (Eloctate and Adynovate) in adolescents with hemophilia A: Is there a difference?
11. Routine clinical care data for population pharmacokinetic modeling: the case for Fanhdi/Alphanate in hemophilia A patients
12. Development and evaluation of a generic population pharmacokinetic model for standard half-life factor VIII for use in dose individualization
13. Evaluation and Calibration of In Silico Models of Thrombin Generation Using Experimental Data from Healthy and Haemophilic Subjects
14. Predicting Individual Changes in Terminal Half-Life After Switching to Extended Half-Life Concentrates in Patients With Severe Hemophilia
15. Correction to: Routine clinical care data for population pharmacokinetic modeling: the case for Fanhdi/Alphanate in hemophilia A patients
16. Revised terminal half‐life of nonacog alfa as derived from extended sampling data: A real‐world study involving 64 haemophilia B patients on nonacog alfa regular prophylaxis
17. 两种重组人凝血因子Ⅷ制剂在血友病A患者中的群体药代动力学研究
18. Pediatric Dose Selection for Therapeutic Proteins
19. Comparison of single subject and population‐based pharmacokinetics for optimizing prophylaxis with simoctocog alfa in patients with haemophilia A
20. Terminal half-life of FVIII and FIX according to age, blood group and concentrate type: data from the WAPPS database
21. Limited sampling strategies for accurate determination of extended half‐life factor VIII pharmacokinetics in severe haemophilia A patients
22. Pharmacokinetic implications of dosing emicizumab based on vial size: A simulation study
23. Not All Patients Benefit from Switching to Ehl: Results from the Wapps Database
24. Terminal Half-Life of Factor VIII/IX According to Age and Blood Group Based on 8550 Assessments
25. Development and evaluation of the population pharmacokinetic models for FVIII and FIX concentrates of the WAPPS‐Hemo project
26. A comparison of methods for prediction of pharmacokinetics across factor concentrate switching in hemophilia patients
27. Development and Validation of a Population-Pharmacokinetic Model for Rurioctacog Alfa Pegol (Adynovate®): A Report on Behalf of the WAPPS-Hemo Investigators Ad Hoc Subgroup
28. Biodistribution and Physiologically-Based Pharmacokinetic Modeling of Gold Nanoparticles in Mice with Interspecies Extrapolation
29. Tissue factor pathway inhibitor is the main determinant of thrombin generation in haemophilic patients
30. Creating a Population Model for PK-Tailored Dosing Using Real-World Data from the Web-Accessible Population Pharmacokinetic Service-Hemophilia (WAPPS-Hemo) Platform
31. Toward a patient specific level of anti-haemophilic factor based on thrombin generation : Contributions of experimental approaches and dynamic modeling of the coagulation cascade
32. Vers une définition patient-spécifique du taux cible de facteur anti-hémophilique à partir de la génération de thrombine : Apports des approches expérimentales et des modèles dynamiques de la cascade de la coagulation
33. Multicentre pharmacokinetic evaluation of rFVIII‐Fc (efmoroctocog alfa) in a real life and comparison with non‐extended half‐life FVIII concentrates.
34. Development and Validation of a Population-Pharmacokinetic Model for Rurioctacog Alfa Pegol (Adynovate®): A Report on Behalf of the WAPPS-Hemo Investigators Ad Hoc Subgroup.
35. A method for the quantitative extraction of gold nanoparticles from human bronchoalveolar lavage fluids through a glycerol gradient
36. Modeling of Body Weight Metrics for Effective and Cost-Efficient Conventional Factor VIII Dosing in Hemophilia A Prophylaxis
37. Predicting Individual Changes in Terminal Half‐Life After Switching to Extended Half‐Life Concentrates in Patients With Severe Hemophilia.
38. Integrated Electrochemical Aptamer Biosensing and Colorimetric pH Monitoring via Hydrogel Microneedle Assays for Assessing Antibiotic Treatment.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.